MiNK Therapeutics jumps after first patient dosed in lung injury study

Mink Therapeutics

28/05/2026 14:49

** Shares of drug developer MiNK Therapeutics INKT.O rise 10.8% to $11.28 
** The firm says it has dosed the first patient in a mid-stage study of agenT-797, its experimental cell therapy for severe acute lung injury and critical illness — a condition where patients struggle to breathe and may need ventilator support 
** Study will test whether adding agenT-797 to standard care can help patients survive, recover faster in ICU and spend fewer days on ventilators - INKT 
** Adds that severe acute lung injury carries an 40%+ death rate, with no approved treatment shown to lower mortality
** Trial began in Ukraine, with U.S. site expansion underway; preliminary data expected in H2 2026 - INKT
** Including session's move, INKT up 0.13% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))